

Special Issue

Adrenocortical Carcinoma: From Pathophysiology to Current and Emerging Therapeutic Approaches

Message from the Guest Editor

Adrenocortical carcinoma (ACC) developing from the adrenal gland is a rare endocrine malignancy with a poor prognosis. Currently, surgery remains the first line of treatment. Adjuvant therapy with mitotane either alone or in combination with chemotherapy is the standard of care treatment for ACC. Recently, novel pathways that can be targets in ACC, such as insulin growth factor 2 (IGF2), beta-catenin pathway, and other pathways, have been identified. This resulted in several drugs targeting these pathways that have entered clinical trials. Despite advances in the development of novel treatment methods, ACC still has a dismal prognosis. Currently, immunotherapy has emerged as an important therapeutic option for several cancer models. However, the role of immunotherapy is not clear. Novel targets and treatments that can benefit ACC patients are still emerging. Therefore, the focus of this Special Issue will be on how the pathophysiology of ACC development drives the current as well as novel emerging therapies that can be of greater benefit to ACC patients.

Guest Editor

Dr. Chitra Subramanian
Department of Surgery, University of Michigan, Ann Arbor, MI, USA

Deadline for manuscript submissions

closed (30 April 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/40116

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).